Single Agent Belantamab Mafodotin Shows Deep and Durable Responses in Final Analysis of RRMM Study
December 12th 2022In a final analysis of the DREAMM-2 study, results showed the rapid and durable responses of belantamab mafodotin continued in patients with relapsed/refractory multiple myeloma despite ocular toxicities.
Read More
Acalabrutinib Appears to Have Quicker Time to Next Therapy Than Ibrutinib in Patients With CLL
December 12th 2022Patients with chronic lymphocytic leukemia on frontline acalabrutinib were more likely to switch to another therapy or intensify their treatment earlier on, compared to those on ibrutinib, according to real-world study data.
Read More
Belantamb Mafodotin Shows PFS Benefit and Tolerable Safety in R/R Multiple Myeloma
December 12th 2022Compared with standard of care regimens for triple-class exposed, relapsed or refractory multiple myeloma, belantamb mafodotin with pomalidomide and dexamethasone extended progression-free survival without sacrificing safety.
Read More
Lenalidomide/ Rituximab Extends 5-Year PFS on R/R Indolent Non-Hodgkin Lymphoma
December 11th 2022Five-year follow up results from the phase 3 AUGMENT trial show that lenalidomide plus rituximab produced enhanced progression-free survival in patients with relapsed/refractory indolent non-Hodgkin lymphoma.
Read More
Obintutuzumab Given Prior to Fixed-Duration Glofitamab Shows Durable Responses in R/R MCL
December 10th 2022Pretreatment with Obinutuzumab aids fixed-duration regimen of glofitamab in high complete responses among a group of heavily pretreated patients with relapsed or refractory mantle cell lymphoma.
Read More
Responses to Cilta-Cel Durable for Nearly 2 Years Across Several R/R Multiple Myeloma Subgroups
December 15th 2021Updated findings from the CARTITUDE-1 trial presented at the 2021 ASH Annual Meeting and Exposition show that the use of a CAR T-cell therapy resulted in durable responses that lasted at nearly 2 years of follow-up across most subgroups with relapsed/refractory multiple myeloma.
Read More